Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.51B 4.1B 3.78B 3.41B 6.44B 422B 6.69B 45.59B 18.03B 227B 16.93B 16.57B 719B P/E 2026 *
-71.9x
P/E 2027 * -589x
Enterprise Value 4.27B 3.88B 3.58B 3.23B 6.1B 399B 6.34B 43.19B 17.08B 215B 16.04B 15.7B 681B EV / Sales 2026 *
13.9x
EV / Sales 2027 * 11.4x
Free-Float
97.19%
Yield 2026 *
-
Yield 2027 * -
1 day+2.22%
1 week-5.85%
Current month+6.94%
1 month+18.61%
3 months+15.16%
6 months+122.06%
Current year+75.43%
1 week 27.29
Extreme 27.29
32.21
1 month 23.82
Extreme 23.82
32.21
Current year 12
Extreme 12
32.21
1 year 12
Extreme 12
32.21
3 years 2.28
Extreme 2.28
32.21
5 years 2.28
Extreme 2.28
32.21
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Exercice

Chairperson

35,643 0.0223%
29/10/26 Exercice

Chairperson

35,643 0.0223%
26/10/26 Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
+2.22%-5.85%+102.06%+606.95% 4.51B
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-0.98%+12.97%+118.46% 46.98B
-2.69%-7.62%+16.77%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-18.72%+140.13%+665.60% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+4.96%-36.93%+398.61% 26.96B
Average -0.74%-2.32%+41.34%+216.86% 41B
Weighted average by Cap. -0.96%-1.55%+34.92%+153.32%

Financials

2026 *2027 *
Net sales 307M 279M 257M 232M 438M 28.69B 455M 3.1B 1.23B 15.48B 1.15B 1.13B 48.91B 373M 339M 313M 282M 533M 34.88B 554M 3.77B 1.49B 18.82B 1.4B 1.37B 59.47B
Net income -63.71M -57.84M -53.43M -48.2M -91M -5.95B -94.48M -644M -255M -3.21B -239M -234M -10.15B -8.3M -7.53M -6.96M -6.28M -11.85M -775M -12.3M -83.83M -33.16M -418M -31.12M -30.47M -1.32B
Net Debt -238M -216M -199M -180M -339M -22.2B -352M -2.4B -950M -11.98B -892M -873M -37.85B -266M -242M -223M -202M -381M -24.9B -395M -2.69B -1.07B -13.44B -1B -979M -42.45B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
17/11/26 USD 28.49 +2.22% 1,885,940
16/11/26 USD 27.87 -4.03% 2,657,890
13/11/26 USD 29.04 -1.49% 2,063,762
12/11/26 USD 29.48 -1.54% 1,920,480
11/11/26 USD 29.94 +1.98% 2,645,755
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.49USD
Average target price
32.57USD
Spread / Average Target
+14.33%
  1. Stock Market
  2. Stocks
  3. ADPT Stock